Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
Alpine Immune Sciences to participate in healthcare conferences
09/05/2023 - 04:30 PM
SEATTLE --(BUSINESS WIRE)--
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.
Thursday, September 7th , the Company will host investor meetings at Citi’s 18th Annual BioPharma Conference in Boston, MA.
Wednesday, September 13th at 10:50am ET/7:50am PT, the Company will participate in a fireside chat and also host investor meetings at the 21st Annual Morgan Stanley Global Healthcare Conference in New York, NY .
A live webcast of the Morgan Stanley fireside chat will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com . Follow @AlpineImmuneSci on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905389290/en/
Media and Investor Relations Contact:
Temre Johnson
Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com
media@alpineimmunesciences.com
Source: Alpine Immune Sciences, Inc.
Alpine Immune Sciences Inc
ALPN Rankings
#329 Ranked by Stock Gains
ALPN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Seattle
About ALPN
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.